BRIEF-Cytrx granted type b pre-nda meeting with U.S. FDA for registration pathway with aldoxorubicin
January 04, 2017 at 09:22 AM EST
* Cytrx granted type b pre-nda meeting with U.S. FDA for registration pathway with aldoxorubicin as a treatment for patients with relapsed soft tissue sarcomas
